share_log

Koshinski Asset Management Inc. Trims Stock Position in ShockWave Medical, Inc. (NASDAQ:SWAV)

Koshinski Asset Management Inc. Trims Stock Position in ShockWave Medical, Inc. (NASDAQ:SWAV)

科辛斯基资产管理公司调整冲击波医疗公司的股票头寸(纳斯达克代码：SWAV)
Defense World ·  2022/09/24 06:21

Koshinski Asset Management Inc. lessened its holdings in shares of ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating) by 7.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,365 shares of the company's stock after selling 115 shares during the period. Koshinski Asset Management Inc.'s holdings in ShockWave Medical were worth $261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

根据科辛斯基资产管理公司在提交给美国证券交易委员会(美国证券交易委员会)的最新Form 13F文件中的说法，该公司在第二季度减持了ShockWave Medical，Inc.的股票7.8%。该基金在此期间出售了115股后，持有1,365股该公司股票。截至最近提交给美国证券交易委员会(Securities and Exchange Commission，美国证券交易委员会)的文件，科辛斯基资产管理公司持有的Shockwave Medical股份价值261,000美元。

Other institutional investors have also recently made changes to their positions in the company. Lincoln National Corp purchased a new position in shares of ShockWave Medical during the first quarter worth $211,000. Level Four Advisory Services LLC grew its position in ShockWave Medical by 21.2% during the first quarter. Level Four Advisory Services LLC now owns 4,426 shares of the company's stock valued at $918,000 after buying an additional 773 shares during the period. Wealth Dimensions Group Ltd. acquired a new stake in ShockWave Medical during the first quarter valued at $207,000. HM Payson & Co. acquired a new stake in ShockWave Medical during the fourth quarter valued at $77,000. Finally, Avestar Capital LLC acquired a new stake in ShockWave Medical during the first quarter valued at $413,000. Hedge funds and other institutional investors own 95.40% of the company's stock.

其他机构投资者最近也对他们在该公司的头寸进行了调整。林肯国家公司在第一季度购买了ShockWave Medical的新头寸，价值211,000美元。Level Four Consulting Services LLC在第一季度将其在Shockwave Medical的头寸增加了21.2%。Level Four Consulting Services LLC现在拥有4426股该公司的股票，价值91.8万美元，在此期间又购买了773股。财富维度集团有限公司在第一季度收购了Shockwave Medical的新股份，价值20.7万美元。HM Payson&Co.在第四季度以77,000美元的价格收购了Shockwave Medical的新股份。最后，Avestar Capital LLC在第一季度收购了ShockWave Medical的新股份，价值41.3万美元。对冲基金和其他机构投资者持有该公司95.40%的股票。

Get
到达
ShockWave Medical
冲击波医疗
alerts:
警报：

Analyst Upgrades and Downgrades

分析师升级和下调评级

SWAV has been the topic of several analyst reports. Morgan Stanley raised their price target on shares of ShockWave Medical from $201.00 to $255.00 and gave the company an "equal weight" rating in a research report on Tuesday, August 9th. Oppenheimer lowered shares of ShockWave Medical from a "market perform" rating to an "underperform" rating and set a $165.00 price target on the stock. in a research report on Tuesday, September 6th. Wells Fargo & Company raised their price target on shares of ShockWave Medical from $176.00 to $255.00 and gave the company an "overweight" rating in a research report on Tuesday, August 9th. Piper Sandler lifted their target price on shares of ShockWave Medical from $278.00 to $338.00 and gave the company an "overweight" rating in a research report on Monday, August 29th. Finally, Canaccord Genuity Group lifted their target price on shares of ShockWave Medical from $232.00 to $256.00 and gave the company a "buy" rating in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $246.50.

SWAV一直是几份分析师报告的主题。8月9日，摩根士丹利在一份研究报告中将冲击波医疗股份的目标价从201.00美元上调至255.00美元，并给予该公司“同等权重”的评级。奥本海默将Shockwave Medical的股票评级从“市场表现”下调至“表现不佳”，并为该股设定了165.00美元的目标价。在9月6日星期二的一份研究报告中。富国银行将Shockwave Medical的股票目标价从176.00美元上调至255.00美元，并在8月9日周二的一份研究报告中给予该公司“增持”评级。8月29日，派珀·桑德勒在一份研究报告中将Shockwave Medical的股票目标价从278.00美元上调至338.00美元，并给予该公司“增持”评级。最后，Cancord Genuity集团在8月9日周二的一份研究报告中将Shockwave Medical的目标价从232.00美元上调至256.00美元，并给予该公司“买入”评级。一位股票研究分析师对该股的评级为卖出，一位分析师给出了持有评级，七位分析师给出了买入评级。根据MarketBeat.com的数据，该股目前的普遍评级为“中等买入”，平均目标价为246.50美元。

Insiders Place Their Bets

内部人士下注

In other ShockWave Medical news, insider Isaac Zacharias sold 4,000 shares of ShockWave Medical stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $198.00, for a total transaction of $792,000.00. Following the transaction, the insider now directly owns 78,563 shares of the company's stock, valued at $15,555,474. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through
在另一则Shockwave Medical新闻中，内部人士Isaac Zacharias在一笔日期为6月27日星期一的交易中出售了4,000股Shockwave Medical股票。这些股票以198.00美元的平均价格出售，总成交额为792,000.00美元。交易完成后，这位内部人士现在直接持有该公司78,563股股票，价值15,555,474美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过
the SEC website
美国证券交易委员会网站
. In other ShockWave Medical news, insider Isaac Zacharias sold 4,000 shares of ShockWave Medical stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $198.00, for a total transaction of $792,000.00. Following the transaction, the insider now directly owns 78,563 shares of the company's stock, valued at $15,555,474. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through
。在另一则Shockwave Medical新闻中，内部人士Isaac Zacharias在一笔日期为6月27日星期一的交易中出售了4,000股Shockwave Medical股票。这些股票以198.00美元的平均价格出售，总成交额为792,000.00美元。交易完成后，这位内部人士现在直接持有该公司78,563股股票，价值15,555,474美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过
the SEC website
美国证券交易委员会网站
. Also, VP Trinh Phung sold 3,500 shares of ShockWave Medical stock in a transaction dated Friday, August 26th. The stock was sold at an average price of $310.76, for a total transaction of $1,087,660.00. Following the transaction, the vice president now directly owns 25,063 shares in the company, valued at $7,788,577.88. The disclosure for this sale can be found
。此外，副总裁Trin h Phung在一笔日期为8月26日(星期五)的交易中出售了3500股Shockwave Medical股票。股票以310.76美元的平均价格出售，总成交金额为1,087,660.00美元。交易完成后，总裁副手现在直接持有该公司25,063股股份，价值7,788,577.88美元。关于这次销售的披露可以找到
here
这里
. Insiders have sold 108,700 shares of company stock valued at $30,247,696 over the last ninety days. Company insiders own 3.90% of the company's stock.
。在过去的90天里，内部人士已经出售了108,700股公司股票，价值30,247,696美元。公司内部人士持有该公司3.90%的股份。

ShockWave Medical Stock Performance

冲击波医疗类股表现

SWAV opened at $252.08 on Friday. The firm has a market capitalization of $9.02 billion, a PE ratio of 172.66 and a beta of 1.06. ShockWave Medical, Inc. has a twelve month low of $113.36 and a twelve month high of $314.90. The firm's 50-day moving average price is $264.51 and its 200 day moving average price is $208.82. The company has a current ratio of 5.32, a quick ratio of 4.41 and a debt-to-equity ratio of 0.02.

上周五，SWAV股开盘报252.08美元。该公司市值为90.2亿美元，市盈率为172.66，贝塔系数为1.06.Shockwave Medical，Inc.的12个月低点为113.36美元，12个月高位为314.90美元。该公司的50日移动均线价格为264.51美元，200日移动均线价格为208.82美元。该公司的流动比率为5.32，速动比率为4.41，债务权益比率为0.02。

ShockWave Medical (NASDAQ:SWAV – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The company reported $0.68 earnings per share for the quarter, topping analysts' consensus estimates of $0.43 by $0.25. The firm had revenue of $120.70 million for the quarter, compared to analyst estimates of $107.51 million. ShockWave Medical had a net margin of 15.11% and a return on equity of 21.25%. ShockWave Medical's quarterly revenue was up 115.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.01) earnings per share. As a group, sell-side analysts expect that ShockWave Medical, Inc. will post 2.57 EPS for the current fiscal year.

冲击波医疗(纳斯达克：SWAV-GET评级)最近一次公布季度收益是在8月8日星期一。该公司公布本季度每股收益为0.68美元，比分析师普遍预期的0.43美元高出0.25美元。该公司本季度营收为1.207亿美元，而分析师预期为1.0751亿美元。Shockwave Medical的净利润率为15.11%，股本回报率为21.25%。冲击波医疗公司的季度收入同比增长了115.5%。去年同期，该业务公布的每股收益为(0.01美元)。作为一个整体，卖方分析师预计Shockwave Medical，Inc.本财年每股收益将达到2.57美元。

About ShockWave Medical

关于冲击波医疗

(Get Rating)

(获取评级)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Shockwave Medical，Inc.是一家医疗设备公司，致力于开发和商业化血管内碎石技术，用于治疗全球外周血管、冠状动脉和心脏瓣膜疾病患者的钙化斑块。该公司提供用于治疗膝关节以上外周动脉疾病(PAD)的M5导管；用于治疗冠状动脉疾病的C2导管；以及用于治疗膝盖以下PAD的S4导管。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on ShockWave Medical (SWAV)
  • MarketBeat: Week in Review 9/19 – 9/23
  • Why Does Tesla Stock Remain Resilient?
  • Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
  • 2 Semiconductor Stocks To Watch For Reversals
  • Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
  • 免费获取StockNews.com关于Shockwave Medical(SWAV)的研究报告
  • MarketBeat：回顾一周9/19-9/23
  • 为什么特斯拉的股票保持弹性？
  • 小盘股的裁员是楼市的晴雨表吗？
  • 需要关注的2只半导体类股走势逆转
  • 好市多盈利后价格疲软是买入的好时机吗？

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.

接受《冲击波医学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对ShockWave Medical和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发